50 related articles for article (PubMed ID: 34979464)
1. Design, synthesis and SAR study of Fluorine-containing 3rd-generation taxoids.
Wang C; Chen L; Sun Y; Guo W; Taouil AK; Ojima I
Bioorg Chem; 2022 Feb; 119():105578. PubMed ID: 34979464
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of Novel 3'-Difluorovinyl Taxoids.
Kuznetsova L; Sun L; Chen J; Zhao X; Seitz J; Das M; Li Y; Veith JM; Pera P; Bernacki RJ; Xia S; Horwitz SB; Ojima I
J Fluor Chem; 2012 Nov; 143():177-188. PubMed ID: 23139432
[TBL] [Abstract][Full Text] [Related]
3. Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.
He Z; Schulz A; Wan X; Seitz J; Bludau H; Alakhova DY; Darr DB; Perou CM; Jordan R; Ojima I; Kabanov AV; Luxenhofer R
J Control Release; 2015 Jun; 208():67-75. PubMed ID: 25725361
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate.
Seitz JD; Vineberg JG; Herlihy E; Park B; Melief E; Ojima I
Bioorg Med Chem; 2015 May; 23(9):2187-94. PubMed ID: 25819334
[TBL] [Abstract][Full Text] [Related]
5. Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
Ojima I; Wang X; Jing Y; Wang C
J Nat Prod; 2018 Mar; 81(3):703-721. PubMed ID: 29468872
[TBL] [Abstract][Full Text] [Related]
6. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.
Pepe A; Sun L; Zanardi I; Wu X; Ferlini C; Fontana G; Bombardelli E; Ojima I
Bioorg Med Chem Lett; 2009 Jun; 19(12):3300-4. PubMed ID: 19423340
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor activity of novel taxoids in anaplastic thyroid cancer.
Wang M; Wang C; Feng C; Guo W; Chen H; Liu B; Li E; Liu W; Taouil A; Ojima I; Hou P
Endocrine; 2022 Feb; 75(2):465-477. PubMed ID: 34591230
[TBL] [Abstract][Full Text] [Related]
8. Application of the dual-tail approach for the design and synthesis of novel Thiopyrimidine-Benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors.
Abdel-Mohsen HT; El Kerdawy AM; Omar MA; Petreni A; Allam RM; El Diwani HI; Supuran CT
Eur J Med Chem; 2022 Jan; 228():114004. PubMed ID: 34847409
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents.
Nicolaou KC; Valiulin RA
Org Biomol Chem; 2013 Jul; 11(25):4154-63. PubMed ID: 23685867
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the strategic incorporation of fluorine into medicinally active compounds.
Haranahalli K; Honda T; Ojima I
J Fluor Chem; 2019 Jan; 217():29-40. PubMed ID: 31537946
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel cabazitaxel analogues.
Ren S; Zhang M; Wang Y; Guo J; Wang J; Li Y; Ding N
Bioorg Med Chem; 2021 Jul; 41():116224. PubMed ID: 34058663
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).
Coyne CP; Narayanan L
Drug Des Devel Ther; 2016; 10():2575-97. PubMed ID: 27574398
[TBL] [Abstract][Full Text] [Related]
14. Exploring novel fluorine-rich fuberidazole derivatives as hypoxic cancer inhibitors: Design, synthesis, pharmacokinetics, molecular docking, and DFT evaluations.
Taj MB; Raheel A; Ayub R; Alnajeebi AM; Abualnaja M; Habib AH; Alelwani W; Noor S; Ullah S; Al-Sehemi AG; Simsek R; Babteen NA; Alshater H
PLoS One; 2023; 18(2):e0262790. PubMed ID: 36730213
[TBL] [Abstract][Full Text] [Related]
15. Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ.
Ojima I; Awasthi D; Wei L; Haranahalli K
J Fluor Chem; 2017 Apr; 196():44-56. PubMed ID: 28555087
[TBL] [Abstract][Full Text] [Related]
16. Fluoro-labelled sp
Padilla-Pérez MC; Sánchez-Fernández EM; González-Bakker A; Puerta A; Padrón JM; Martín-Loro F; Arroba AI; García Fernández JM; Mellet CO
Eur J Med Chem; 2023 Jul; 255():115390. PubMed ID: 37137247
[TBL] [Abstract][Full Text] [Related]
17. Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications.
Niu ZX; Hu J; Sun JF; Wang YT
Eur J Med Chem; 2024 May; 271():116446. PubMed ID: 38678824
[TBL] [Abstract][Full Text] [Related]
18. Total synthesis and biological evaluation of fluorinated cryptophycins.
Weiß C; Bogner T; Sammet B; Sewald N
Beilstein J Org Chem; 2012; 8():2060-6. PubMed ID: 23209540
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of tirbanibulin derivatives: a detailed exploration of the structure-activity relationship for anticancer activity.
Park J; Kang M; Lim A; Cho KJ; Chae CH; Koh B; Jeon H
RSC Adv; 2023 Nov; 13(50):35583-35591. PubMed ID: 38077981
[TBL] [Abstract][Full Text] [Related]
20. In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833).
Wright SW; Farley KA; Han S; Knafels JD; Lee KL
ACS Med Chem Lett; 2024 Apr; 15(4):540-545. PubMed ID: 38628800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
